“Unlike antibody-based vaccines, T-cell-based vaccines kill the infected cell, preventing virus replication, and could provide long-term memory to recipients,” he said.
Biovac CEO Dr Morena Makhoana said the collaboration was a strategic step in the quest to build vaccine-manufacturing capability in Africa.